Literature DB >> 21515436

The bone architecture is enhanced with combined PTH and alendronate treatment compared to monotherapy while maintaining the state of surface mineralization in the OVX rat.

Graeme M Campbell1, R Bernhardt, D Scharnweber, Steven K Boyd.   

Abstract

This study examined the effect of PTH and alendronate alone and in combination on the bone architecture, mineralization, and estimated mechanics in the OVX rat. Female Wistar rats aged 7-9months were assigned to one of five groups: (1) sham+vehicle, (2) OVX+vehicle, (3) OVX+PTH, (4) OVX+alendronate, and (5) OVX+PTH and alendronate. Surgery was performed at baseline (week 0), and biweekly treatment (15μg/kg of alendronate and/or daily (5days/week) 40μg/kg hPTH(1-34)) was administered from week 6 to week 14. Micro-CT scans of the right proximal tibial metaphysis were made in vivo at weeks 0, 6, 8, 10, 12 and 14 and measurements of bone microarchitecture and estimated mechanical parameters (finite element analysis) were made from the images. Synchrotron radiation micro-CT scans of the proximal tibia and fourth lumbar vertebrae were conducted ex vivo at the study endpoint to determine the degree and spatial distribution of the bone mineralization. Alendronate preserved the microarchitecture after OVX, and increased cortical (9%, p<0.05) and trabecular thickness (5%, p<0.05). PTH mono- and combined therapy induced increases in cortical (25-35%, p<0.05) and trabecular thicknesses (46-48%, p<0.05), resulting in a full restoration of bone volume in the PTH group, and an increase beyond baseline in the combined group. Improvements in estimated mechanical outcomes were observed in all treatment groups by the end of the study, with the combined group experiencing the greatest increase in predicted stiffness (63%, p<0.05). Alendronate treatment increased the peak mineral content above the other treatment groups at the trabecular (tibia: 6% above PTH, 6% above combined, L4: 4% above PTH, 4% above combined) and endocortical (tibia: 4% above PTH, 3% above combined, L4: 1% above PTH, 2% above combined) surfaces, while no differences in mineralization between the PTH and combined groups were observed. Combined treatment resulted in more pronounced improvements of the bone architecture than PTH monotherapy, while maintaining the state of mineralization observed with PTH treatment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515436     DOI: 10.1016/j.bone.2011.04.008

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  Can the alendronate dosage be altered when combined with high-frequency loading in osteoporosis treatment?

Authors:  C B Correa; G V Camargos; M Chatterjee; M F Mesquita; A A Del Bel Cury; I Naert; J Duyck; K Vandamme
Journal:  Osteoporos Int       Date:  2016-12-05       Impact factor: 4.507

2.  Enhanced individual trabecular repair and its mechanical implications in parathyroid hormone and alendronate treated rat tibial bone.

Authors:  Allison R Altman; Chantal M J de Bakker; Wei-Ju Tseng; Abhishek Chandra; Ling Qin; X Sherry Liu
Journal:  J Biomech Eng       Date:  2014-12-10       Impact factor: 2.097

3.  Temporal changes in cortical microporosity during estrogen deficiency associated with perilacunar resorption and osteocyte apoptosis: A pilot study.

Authors:  H Allison; L M O'Sullivan; L M McNamara
Journal:  Bone Rep       Date:  2022-05-17

4.  A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment.

Authors:  Allison R Altman; Wei-Ju Tseng; Chantal M J de Bakker; Beom Kang Huh; Abhishek Chandra; Ling Qin; X Sherry Liu
Journal:  Bone       Date:  2014-01-24       Impact factor: 4.398

5.  PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology.

Authors:  Christopher M Bartlow; Megan E Oest; Kenneth A Mann; Nicholas D Zimmerman; Bilal B Butt; Timothy A Damron
Journal:  J Orthop Res       Date:  2016-10-03       Impact factor: 3.494

6.  Secondary alterations in bone mineralisation and trabecular thickening occur after long-term estrogen deficiency in ovariectomised rat tibiae, which do not coincide with initial rapid bone loss.

Authors:  L M O'Sullivan; H Allison; E E Parle; J Schiavi; L M McNamara
Journal:  Osteoporos Int       Date:  2019-11-30       Impact factor: 4.507

7.  Effect of high-frequency loading and parathyroid hormone administration on peri-implant bone healing and osseointegration.

Authors:  Aya Shibamoto; Toru Ogawa; Joke Duyck; Katleen Vandamme; Ignace Naert; Keiichi Sasaki
Journal:  Int J Oral Sci       Date:  2018-03-13       Impact factor: 6.344

Review 8.  Combination Therapy of PTH and Antiresorptive Drugs on Osteoporosis: A Review of Treatment Alternatives.

Authors:  Chenggui Zhang; Chunli Song
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

9.  Structure Model Index Does Not Measure Rods and Plates in Trabecular Bone.

Authors:  Phil L Salmon; Claes Ohlsson; Sandra J Shefelbine; Michael Doube
Journal:  Front Endocrinol (Lausanne)       Date:  2015-10-13       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.